.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
STEP 2 studied semaglutide 2.4 mg in adults with type 2 diabetes and overweight or obesity. At 68 weeks, semaglutide 2.4 mg produced substantially greater weight loss than placebo and greater loss than the 1.0-mg diabetes dose. Glycemic measures and several cardiometabolic outcomes also improved. The study is useful for physicians managing the common triad of diabetes, obesity and cardiovascular risk. It demonstrates that treatment intensity and therapeutic goals can be tailored to the patient's phenotype rather than treating HbA1c in isolation. Gastrointestinal symptoms were common, and long-term continuation is important because obesity is a chronic disease and weight regain can follow treatment withdrawal. In practice, semaglutide should be introduced with clear expectations about dose escalation, nutrition, physical activity and monitoring. The broader lesson is that modern diabetes therapy can simultaneously address glycemic control and excess adiposity, which may improve the overall risk profile of appropriately selected patients.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
STEP 2 studied semaglutide 2.4 mg in adults with type 2 diabetes and overweight or obesity. At 68 weeks, semaglutide 2.4 mg produced substantially greater weight loss than placebo and greater loss than the 1.0-mg diabetes dose. Glycemic measures and several cardiometabolic outcomes also improved. The study is useful for physicians managing the common triad of diabetes, obesity and cardiovascular risk. It demonstrates that treatment intensity and therapeutic goals can be tailored to the patient's phenotype rather than treating HbA1c in isolation. Gastrointestinal symptoms were common, and long-term continuation is important because obesity is a chronic disease and weight regain can follow treatment withdrawal. In practice, semaglutide should be introduced with clear expectations about dose escalation, nutrition, physical activity and monitoring. The broader lesson is that modern diabetes therapy can simultaneously address glycemic control and excess adiposity, which may improve the overall risk profile of appropriately selected patients.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
